Track topics on Twitter Track topics that are important to you
Glaukos reported a net loss of $3.3 million, or $0.10 per diluted share, in the second quarter of 2017 compared with a net income of $2.3 million, or $0.06 per diluted share, in the second quarter of 2016. Net sales increased from $28.6 million a year ago to $41.3 million, an increase of 45%. This was attributed to an increase in global unit volume, higher selling prices and expansion of sales operations in international markets, according to a company press release.
Original Article: Glaukos reports $3.3 million net loss in second quarterNEXT ARTICLE
The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...